Baidu
map

PLOS Path:研究发现人体内一种抑制HIV的广谱抗病毒蛋白

2017-01-22 佚名 生物谷

来自科罗拉多大学波德分校的研究人员发现了一种编码蛋白的叫做Schlafen11(SLFN11)的基因可以诱发针对一系列病毒的广谱免疫反应,其中包括HIV 1型病毒(HIV-1)。这项新研究发表在《PLOS Pathogens》上,研究人员发现SLFN11在黑猩猩和猩猩体内的抗病毒效应是最强的,但是在人体和大猩猩体内作用稍弱一些,这表明随着时间发展这个基因对抗HIV-1的能力出现了种间差


来自科罗拉多大学波德分校的研究人员发现了一种编码蛋白的叫做Schlafen11(SLFN11)的基因可以诱发针对一系列病毒的广谱免疫反应,其中包括HIV 1型病毒(HIV-1)。这项新研究发表在《PLOS Pathogens》上,研究人员发现SLFN11在黑猩猩和猩猩体内的抗病毒效应是最强的,但是在人体和大猩猩体内作用稍弱一些,这表明随着时间发展这个基因对抗HIV-1的能力出现了种间差异。

“这项研究表明HIV-1可以利用人体内这种蛋白功能稍弱的现象。”论文第一作者Alex Stabell说道,他是科罗拉多大学波德分校的博士研究生。

人体免疫系统包含许多可以识别外源RNA病毒信号并防止它们复制的蛋白编码基因,这为抵抗病毒感染提供了基础。HIV-1是人畜共感染的逆转录病毒之一,它可以通过一些未知的机理克服人体的这种抵抗机制,因此可以从灵长类动物体内传播到人身上。

2012年,研究人员发现SLFN11基因编码产物可以在病毒生命早期抑制病毒复制,但是迄今为止还没有研究表明这个基因可以帮助人体抵抗病毒感染。

“免疫系统包含一些哺乳动物基因组里进化最快的基因,我们发现就算是非常相近的物种的免疫系统都有很大的差别,比如人和黑猩猩。” 科罗拉多大学波德分校的副教授Sara Sawyer说道,他是这项研究的资深作者。

为了研究其中的原因,研究人员分析了美国灵长类动物基因组项目的所有数据,以此研究基因的进化史并比较该基因在不同灵长类动物中的抗病毒作用。

Stabell说道:“我们研究了其他灵长类物种体内这个基因的不同版本,想以此找到随着时间发生的阳性选择,这些基因往往趋向于保守,但是快速适应的逆转录病毒会抑制这个基因的作用。”

他们分析发现了该基因发生种间差异的时间点。他们还发现该基因不仅可以抑制HIV-1,在未感染HIV-1的情况下,这个基因可以通过未优化的外显子广泛的调控一些蛋白表达,可将细胞转化处于抗病毒状态。这项发现为开发针对HIV-1的药物和基因疗法提供了新的途径。

原始出处

Alex C. Stabell, John Hawkins, Manqing Li, Xia Gao, Michael David, William H. Press, Sara L. Sawyer.Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins. PLOS Pathogens, 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705261, encodeId=778f1e0526156, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Fri Apr 21 21:02:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927187, encodeId=fe60192e18735, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Tue Nov 14 13:02:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753171, encodeId=b4a81e5317109, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 22 13:02:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292349, encodeId=e7131292349a7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172132, encodeId=227f1e2132ae, content=生命体奥妙无穷!期待更进一步的探索。, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/GqMboaVWkPad3W1U38NyylfYmjIh9pgYaUHQhhpvGExice2QfumibEcZ9Pe8zsSpzMclvoylI5pBGrQcDUibF3arA/132, createdBy=903b1950096, createdName=1e110619m74(暂无匿称), createdTime=Mon Jan 23 10:54:34 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172102, encodeId=ec931e2102c9, content=但愿能有新突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160530/IMG574B6FCC15A9D2891.jpg, createdBy=1fbc1611028, createdName=yangwf, createdTime=Mon Jan 23 09:14:42 CST 2017, time=2017-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705261, encodeId=778f1e0526156, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Fri Apr 21 21:02:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927187, encodeId=fe60192e18735, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Tue Nov 14 13:02:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753171, encodeId=b4a81e5317109, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 22 13:02:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292349, encodeId=e7131292349a7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172132, encodeId=227f1e2132ae, content=生命体奥妙无穷!期待更进一步的探索。, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/GqMboaVWkPad3W1U38NyylfYmjIh9pgYaUHQhhpvGExice2QfumibEcZ9Pe8zsSpzMclvoylI5pBGrQcDUibF3arA/132, createdBy=903b1950096, createdName=1e110619m74(暂无匿称), createdTime=Mon Jan 23 10:54:34 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172102, encodeId=ec931e2102c9, content=但愿能有新突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160530/IMG574B6FCC15A9D2891.jpg, createdBy=1fbc1611028, createdName=yangwf, createdTime=Mon Jan 23 09:14:42 CST 2017, time=2017-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1705261, encodeId=778f1e0526156, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Fri Apr 21 21:02:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927187, encodeId=fe60192e18735, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Tue Nov 14 13:02:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753171, encodeId=b4a81e5317109, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 22 13:02:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292349, encodeId=e7131292349a7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172132, encodeId=227f1e2132ae, content=生命体奥妙无穷!期待更进一步的探索。, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/GqMboaVWkPad3W1U38NyylfYmjIh9pgYaUHQhhpvGExice2QfumibEcZ9Pe8zsSpzMclvoylI5pBGrQcDUibF3arA/132, createdBy=903b1950096, createdName=1e110619m74(暂无匿称), createdTime=Mon Jan 23 10:54:34 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172102, encodeId=ec931e2102c9, content=但愿能有新突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160530/IMG574B6FCC15A9D2891.jpg, createdBy=1fbc1611028, createdName=yangwf, createdTime=Mon Jan 23 09:14:42 CST 2017, time=2017-01-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705261, encodeId=778f1e0526156, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Fri Apr 21 21:02:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927187, encodeId=fe60192e18735, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Tue Nov 14 13:02:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753171, encodeId=b4a81e5317109, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 22 13:02:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292349, encodeId=e7131292349a7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172132, encodeId=227f1e2132ae, content=生命体奥妙无穷!期待更进一步的探索。, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/GqMboaVWkPad3W1U38NyylfYmjIh9pgYaUHQhhpvGExice2QfumibEcZ9Pe8zsSpzMclvoylI5pBGrQcDUibF3arA/132, createdBy=903b1950096, createdName=1e110619m74(暂无匿称), createdTime=Mon Jan 23 10:54:34 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172102, encodeId=ec931e2102c9, content=但愿能有新突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160530/IMG574B6FCC15A9D2891.jpg, createdBy=1fbc1611028, createdName=yangwf, createdTime=Mon Jan 23 09:14:42 CST 2017, time=2017-01-23, status=1, ipAttribution=)]
    2017-01-24 yahu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1705261, encodeId=778f1e0526156, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Fri Apr 21 21:02:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927187, encodeId=fe60192e18735, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Tue Nov 14 13:02:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753171, encodeId=b4a81e5317109, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 22 13:02:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292349, encodeId=e7131292349a7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172132, encodeId=227f1e2132ae, content=生命体奥妙无穷!期待更进一步的探索。, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/GqMboaVWkPad3W1U38NyylfYmjIh9pgYaUHQhhpvGExice2QfumibEcZ9Pe8zsSpzMclvoylI5pBGrQcDUibF3arA/132, createdBy=903b1950096, createdName=1e110619m74(暂无匿称), createdTime=Mon Jan 23 10:54:34 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172102, encodeId=ec931e2102c9, content=但愿能有新突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160530/IMG574B6FCC15A9D2891.jpg, createdBy=1fbc1611028, createdName=yangwf, createdTime=Mon Jan 23 09:14:42 CST 2017, time=2017-01-23, status=1, ipAttribution=)]
    2017-01-23 1e110619m74(暂无匿称)

    生命体奥妙无穷!期待更进一步的探索。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1705261, encodeId=778f1e0526156, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Fri Apr 21 21:02:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927187, encodeId=fe60192e18735, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Tue Nov 14 13:02:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753171, encodeId=b4a81e5317109, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 22 13:02:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292349, encodeId=e7131292349a7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Jan 24 08:02:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172132, encodeId=227f1e2132ae, content=生命体奥妙无穷!期待更进一步的探索。, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/GqMboaVWkPad3W1U38NyylfYmjIh9pgYaUHQhhpvGExice2QfumibEcZ9Pe8zsSpzMclvoylI5pBGrQcDUibF3arA/132, createdBy=903b1950096, createdName=1e110619m74(暂无匿称), createdTime=Mon Jan 23 10:54:34 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172102, encodeId=ec931e2102c9, content=但愿能有新突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160530/IMG574B6FCC15A9D2891.jpg, createdBy=1fbc1611028, createdName=yangwf, createdTime=Mon Jan 23 09:14:42 CST 2017, time=2017-01-23, status=1, ipAttribution=)]
    2017-01-23 yangwf

    但愿能有新突破

    0

相关资讯

PNAS:重大突破!科学家阐明HIV如何成功感染机体

图片来源:medicalxpress.com 一旦进行性接触,AIDS病毒就会克服多种屏障寻找正确的靶向细胞并且建立新型感染,病毒往往会横穿生殖道粘膜,强行通过紧密组装的上皮细胞最终实现入侵机体的目的,但在病毒感染机体时它们往往需要克服机体的免疫警钟—1型干扰素,实际上据很多研究结果表明,在1000例无防护的性接触个体中,仅会有1人最终成功感染HIV-1。 来自宾夕法尼亚大学的研究

Eur Heart J:感染HIV的ACS患者接受双联抗血小板治疗后血小板活性会咋样?

相比于未感染HIV的ACS患者,感染HIV的ACS患者血小板活性水平升高,并且对P2Y12抑制剂和阿司匹林有较高的HPR比例。这些结果对HIV感染者复发性缺血性事件风险增加提供了潜在的解释。

Nat Genet:利用CRISPR鉴定出潜在的HIV治疗靶标

在一项新的研究中,来自美国怀特海德研究所、拉根研究所和布罗德研究所的研究人员利用CRISPR-Cas9基因编辑技术鉴定出三个有望用于治疗HIV感染的新靶标。他们描述了如何利用CRISPR筛选HIV感染但不是细胞存活所必需的人基因的方法鉴定出5个基因---它们的三个在早前的利用RNA干扰(RNAi)的研究中并未被鉴定出。他们的方法也能够被用来鉴定出针对其他的病毒性病原体的治疗性靶标。相关研究结

TED: 我们有对付HIV和流感病毒的疫苗策略吗?

疫苗预先训练我们身体怎样识别和压制特殊的入侵者。 A vaccine trains the body in advance how to recognize and neutralize a specific invader.演讲实录:你是否曾经担心过什么将置于你于死地?心脏病或者癌症,还是车祸呢?我们大多数担心一些我们无法控制的事情:比如战争、恐怖主义、 或者是刚刚在海地发生的悲惨的地震。那

HIV如何诡计多端 让科学家防不胜防?

1981年,自第一例艾滋病患者被发现以来,人们才开始慢慢了解HIV和AIDS,随着科学家们30多年的努力研究,他们在艾滋病研究领域取得了众多可喜的研究成果,研究者不光阐明了HIV感染宿主的分子机制,还对抵御耐药性菌株提出了可行性的策略,尽管如此,HIV病毒还会“另辟蹊径”寻找求生出路,让科学家们防不胜防,如今科学家们还继续对此深入研究,本文中,小编整理了多篇研究来阐释HIV到底

年度巨献—2016年HIV研究领域的创新性突破疗法

长期以来,科学家们都在不遗余力地研究寻找治疗HIV的创新性疗法,随着研究的不断深入,免疫疗法、基因疗法等等多种疗法在治疗,甚至治愈HIV感染上都展现出了巨大的潜力,2016年即将过去,崭新的2017在向我们招手,在过去的一年里,科学家们在艾滋病疗法研究领域又有哪些创新性的结果呢?请跟随小编的脚步,慢慢来学习! 【1】Nat Genet:利用CRISPR鉴定出潜在的HIV治疗靶标

Baidu
map
Baidu
map
Baidu
map